Comparative efficacy of intraoperative radiotherapy and external boost irradiation in early-stage breast cancer: a systematic review and meta-analysis.
Breast cancer
External irradiation therapy
Intraoperative radiation therapy
Meta-analysis
RCT
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
06
2023
accepted:
01
08
2023
medline:
26
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
External boost radiotherapy (EBRT) and intraoperative radiotherapy (IORT) are shown to be effective in patients with early-stage breast cancer. However, the difference between IORT and EBRT for patients' prognosis remains to be elucidated. The purpose of this meta-analysis is to investigate differences in local recurrence (LR), distant metastases, disease free survival (DFS), and overall survival (OS) between these two therapies. We searched the Cochrane Library, PubMed, Web of Science and Embase, from inception to Jan 10th, 2022. We used The Cochrane risk-of-bias assessment tool to assess the risk of bias of the included studies, and the STATA15.0 tool was used for the meta-analyses. Eight studies were ultimately included. Meta-analysis demonstrated that there was an inconsistent finding in the long-term risk of LR between the two radiotherapies, and there was no significant difference in short-term risk of LR, the metastasis rate, DFS, and OS IORT would be more convenient, less time-consuming, less costly, and more effective at reducing side effects and toxicity. However, these benefits must be balanced against the potential for increased risk of LR in the long term.
Identifiants
pubmed: 37744215
doi: 10.7717/peerj.15949
pii: 15949
pmc: PMC10512934
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15949Informations de copyright
©2023 Liu et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Clin Breast Cancer. 2014 Apr;14(2):141-6
pubmed: 24291378
Br J Cancer. 2013 Jan 15;108(1):179-82
pubmed: 23257897
Strahlenther Onkol. 2017 Jan;193(1):62-69
pubmed: 27858093
JAMA Oncol. 2020 Jul 1;6(7):e200249
pubmed: 32239210
Lancet. 2010 Jul 10;376(9735):91-102
pubmed: 20570343
Lancet. 1986 May 24;1(8491):1217-8
pubmed: 2422515
Chirurgia (Bucur). 2021 Mar-Apr;116(2 Suppl):84-90
pubmed: 33963697
J Clin Oncol. 1999 Aug;17(8):2326-33
pubmed: 10561294
BMJ Open. 2017 Aug 17;7(8):e014944
pubmed: 28819067
BMJ. 2020 Aug 19;370:m2836
pubmed: 32816842
Lancet Oncol. 2021 May;22(5):597-608
pubmed: 33845035
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):709-18
pubmed: 26972643
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Breast Cancer Res Treat. 2013 Aug;140(3):519-25
pubmed: 23877341
Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):985-995
pubmed: 35227789
Int J Surg Oncol. 2021 Apr 16;2021:2476527
pubmed: 33953982
Br J Cancer. 2021 Aug;125(3):380-389
pubmed: 34035435
Front Oncol. 2020 Oct 08;10:550327
pubmed: 33134162
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Int J Colorectal Dis. 1989 Aug;4(3):167-71
pubmed: 2768999
JAMA. 2022 Feb 22;327(8):727-736
pubmed: 35191924
Ann Oncol. 2001 Jul;12(7):997-1003
pubmed: 11521809
N Engl J Med. 1986 Jun 5;314(23):1518
pubmed: 2422555
Chirurgia (Bucur). 2017 Jul-Aug;112(4):387-393
pubmed: 28862114
BMC Med. 2023 Jul 3;21(1):239
pubmed: 37400822
Health Technol Assess. 2016 Sep;20(73):1-188
pubmed: 27689969
Breast Cancer Res. 2021 Apr 13;23(1):46
pubmed: 33849606
Strahlenther Onkol. 2019 Jul;195(7):640-647
pubmed: 30796496
Br J Cancer. 2021 Nov;125(10):1443-1449
pubmed: 34408284